Serum markers for type IV collagen and type III procollagen in the myelofibrosis-osteomyelosclerosis syndrome and other chronic myeloproliferative disorders. 1986

H Hasselbalch, and P Junker, and I Lisse, and K D Bentsen, and L Risteli, and J Risteli

Myelofibrosis is characterized by excessive deposition of interstitial and basement membrane collagens in the bone marrow. In this study, specific radioimmunoassays for the aminoterminal propeptide of type III procollagen and for the 7S collagen domain of type IV (basement membrane) collagen were used to determine how this accumulation is reflected in serum. Of the 41 patients with chronic myeloproliferative disorders studied, the highest levels of both parameters were found in idiopathic myelofibrosis and in chronic myelogenous leukaemia associated with bone marrow fibrosis. Increasing degrees of bone marrow fibrosis were accompanied by increasing serum concentrations of both markers, except for osteomyelosclerosis, where notably low values were seen. Pathologically high values of one or both parameters were also found in a few patients with polycythaemia vera or a transitional myeloproliferative disorder. The antigens related to type III procollagen and type IV collagen correlated significantly with each other and with the leucocyte count. These parameters should provide noninvasive means for following the accumulation of interstitial and basement membrane collagens in the bone marrow.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009196 Myeloproliferative Disorders Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE. Disorder, Myeloproliferative,Disorders, Myeloproliferative,Myeloproliferative Disorder
D010019 Osteomyelitis INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA. Osteomyelitides
D011347 Procollagen A biosynthetic precursor of collagen containing additional amino acid sequences at the amino-terminal and carboxyl-terminal ends of the polypeptide chains. Protocollagen,Procollagen Type M
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003094 Collagen A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH). Avicon,Avitene,Collagen Felt,Collagen Fleece,Collagenfleece,Collastat,Dermodress,Microfibril Collagen Hemostat,Pangen,Zyderm,alpha-Collagen,Collagen Hemostat, Microfibril,alpha Collagen
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Hasselbalch, and P Junker, and I Lisse, and K D Bentsen, and L Risteli, and J Risteli
January 1988, Acta medica Hungarica,
H Hasselbalch, and P Junker, and I Lisse, and K D Bentsen, and L Risteli, and J Risteli
December 1994, Japanese journal of cancer research : Gann,
H Hasselbalch, and P Junker, and I Lisse, and K D Bentsen, and L Risteli, and J Risteli
September 1988, Clinical and experimental dermatology,
H Hasselbalch, and P Junker, and I Lisse, and K D Bentsen, and L Risteli, and J Risteli
November 1990, European journal of haematology,
H Hasselbalch, and P Junker, and I Lisse, and K D Bentsen, and L Risteli, and J Risteli
April 1996, Journal of gastroenterology,
H Hasselbalch, and P Junker, and I Lisse, and K D Bentsen, and L Risteli, and J Risteli
February 1991, Clinica chimica acta; international journal of clinical chemistry,
H Hasselbalch, and P Junker, and I Lisse, and K D Bentsen, and L Risteli, and J Risteli
January 1998, Journal of pediatric surgery,
H Hasselbalch, and P Junker, and I Lisse, and K D Bentsen, and L Risteli, and J Risteli
December 1983, American journal of hematology,
H Hasselbalch, and P Junker, and I Lisse, and K D Bentsen, and L Risteli, and J Risteli
April 1956, Acta haematologica,
H Hasselbalch, and P Junker, and I Lisse, and K D Bentsen, and L Risteli, and J Risteli
July 1975, Biochimica et biophysica acta,
Copied contents to your clipboard!